Can nanotechnologies revolutionize the early diagnosis of Alzheimer’s disease?

Alzheimer’s disease affects more than 55 million people worldwide, and its prevalence is expected to double every 20 years. It first manifests as memory and thinking disorders, then progresses to complete loss of autonomy. However, the biological signs of the disease appear long before the first symptoms, sometimes up to 20 years earlier. Two proteins, called beta-amyloid and tau, play a key role in its development. Their accumulation in the brain leads to the progressive destruction of neurons.

Currently, diagnosis relies on expensive and invasive tests, such as lumbar punctures or brain scans. These methods often only detect the disease at an advanced stage, when damage is already irreversible. Earlier detection could change the game, enabling faster and more effective management.

This is where nanotechnologies come into play. Researchers are exploring ultra-sensitive spectroscopic techniques capable of detecting tiny amounts of these proteins in blood, saliva, or urine. These methods use gold or silver nanoparticles, which amplify biomarker signals through a phenomenon called plasmon resonance. For example, some approaches can detect beta-amyloid protein at concentrations a thousand times lower than current tests.

However, these innovations still face major challenges. Results vary between laboratories, and tests must be validated on a large number of patients before they can be used routinely. Additionally, the concentration of these proteins in fluids such as blood or saliva is extremely low, making their detection complex.

Scientists are also working to improve data analysis using artificial intelligence. This could help distinguish relevant signals from biological “noise,” thereby refining diagnostic accuracy. But for these technologies to become a clinical reality, their reliability, reproducibility, and accessibility must be ensured.

The stakes are high: a simple, early, and low-cost diagnosis could not only improve patients’ lives but also reduce the economic burden of this disease, estimated at several trillion dollars per year. Nanotechnologies offer a promising path, but their success will depend on their ability to transition from the laboratory to medical practice.

Media Sources

Reference Document

DOI: https://doi.org/10.1007/s12551-026-01428-9

Title: Nano-based spectroscopic approaches for early diagnosis of Alzheimer’s disease: critical insights into amyloid-β and tau biomarker biology and detection tools

Journal: Biophysical Reviews

Publisher: Springer Science and Business Media LLC

Authors: Andra-Sorina Tatar; Alia Colnita; Ioana-Andreea Brezestean; Sanda Boca